Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.
Abstract
The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.
참고문헌 (49)
- Oh H, "Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment", Clin Mol Hepatol, 22, pp.327~335 (2016)
- Alkhouri N, "Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal", Expert Rev Gastroenterol Hepatol, 3, pp.445~451 (2009)
- Malhi H, "Cellular and molecular mechanisms of liver injury", Gastroenterology, 134, pp.1641~1654 (2008)
- Yang L, "Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice", Hepatology, 59, pp.483~495 (2014)
- Okazaki I, "Non-alcoholic steatohepatitis" (2018), Koonja Publishing Inc
- Miura K, "Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2", Am J Physiol Gastrointest Liver Physiol, 302, pp.G1310~G1321 (2012)
- Tacke F, "Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis", Expert Opin Investig Drugs, 27, pp.301~311 (2018)
- Friedman S, "Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design", Contemp Clin Trials, 47, pp.356~365 (2016)
- Paradis V, "High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis", Hepatology, 34, pp.738~744 (2001)
- Starley BQ, "Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection", Hepatology, 51, pp.1820~1832 (2010)
- Derosa G, "Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents", Drugs, 70, pp.1945~1961 (2010)
- Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
- Schuster S, "NASH: novel therapeutic strategies targeting ASK1 in NASH", Nat Rev Gastroenterol Hepatol, 14, pp.329~330 (2017)
- Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
- Ikenaga N, "Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal", Gut, 66, pp.1697~1708 (2017)
- Harrison SA, "Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis", Gastroenterology, 155, pp.1140~1153 (2018)
- Keely SJ, "The farnesoid X receptor: good for BAD", Cell Mol Gastroenterol Hepatol, 2, pp.725~732 (2016)
- Mudaliar S, "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease", Gastroenterology, 145, pp.574~582 (2013)
- Grygiel-Górniak B, "Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review", Nutr J, 13, pp.17~ (2014)
- Miyahara T, "Peroxisome proliferator-activated receptors and hepatic stellate cell activation", J Biol Chem, 275, pp.35715~35722 (2000)
- van Wagner LB, "The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis", Therap Adv Gastroenterol, 4, pp.249~263 (2011)
- Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Am J Gastroenterol, 107, pp.811~826 (2012)
- Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
- Wadden TA, "Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study", Int J Obes (Lond), 37, pp.1443~1451 (2013)
- Milder TY, "Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis", J Clin Med, 8, pp.E45~ (2019)
- Sumida Y, "Current and future pharmacological therapies for NAFLD", NASH, 2018, pp.53, 362~376
- Shibuya T, "Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study", Diabetes Obes Metab, 20, pp.438~442 (2018)
- Ito D, "Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial", Diabetes Care, 40, pp.1364~1372 (2017)
- Tomita K, "Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice", Hepatology, 59, pp.154~169 (2014)
- Muir K, "Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma", Cancer Res, 73, pp.4722~4731 (2013)
- Filozof C, "Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway", Drugs, 75, pp.1373~1392 (2015)
- Sanyal AJ, "No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial", Gastroenterology, 147, pp.377~384 (2014)
- Scorletti E, "Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study", Hepatology, 60, pp.1211~1221 (2014)
- Wang X, "Ezetimibe prevents the development of non alcoholic fatty liver disease induced by high fat diet in C57BL", 6J mice, 2014, pp.10, 2917~2923
- Loomba R, "Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)", Hepatology, 61, pp.1239~1250 (2015)
- Hirose A, "Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis", Hepatology, 45, pp.1375~1381 (2007)
- Georgescu EF, "Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis", World J Gastroenterol, 15, pp.942~954 (2009)
- McPherson S, "A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis", PLoS One, 12, pp.e0175717~ (2017)
- Connolly JJ, "Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials", J Clin Transl Hepatol, 6, pp.264~275 (2018)
- Abenavoli L, "Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease", Pharmaceuticals (Basel), 11, pp.E104~ (2018)
- Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
- Imoto K, "Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling", Diabetes, 55, pp.1197~1204 (2006)
- Ratziu V, "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)
- Shiffman M, "Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3", 7 activation in subjects with non-alcoholic fatty liver disease, 2019, pp.49, 64~73
- Garcia-Tsao G, "Emricasan (IDN-6556) Lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension", Hepatology, 69, pp.717~728 (2019)
- Safadi R, "The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 12, pp.2085~2091 (2014)
- Harrison SA, "NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind,placebo-controlled, phase 2 trial", Lancet, 391, pp.1174~1185 (2018)
- Sanyal A, "Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial", Lancet, 392, pp.2705~2717 (2019)